1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. AstraZeneca PLC
  6. News
  7. Summary
    AZN   GB0009895292


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Gates, Wellcome pledge $150 mln each to pandemic preparedness group

01/18/2022 | 06:01pm EDT

CHICAGO, Jan 18 (Reuters) - Global health charities the Bill & Melinda Gates Foundation and Wellcome Trust each pledged $150 million to the Coalition for Epidemic Preparedness Innovations (CEPI) to fund its COVID-19 pandemic response and help put it on better footing for future major health crises.

The pledges, announced on Tuesday, come ahead of a March 8 fundraising event sponsored by the UK government that aims to raise $3.5 billion on behalf of CEPI, an international coalition set up five years ago to prepare for future disease threats.

CEPI's five-year strategy aims in part to compress vaccine development timelines to 100 days, around a third of the time it took the world to develop the first COVID-19 vaccines.

"The unprecedented spread of the highly infectious Omicron variant around the world over the past two months exemplifies the ways in which we must be ready both in terms of speed and the scale of our response to future threats," CEPI Chief Executive Richard Hatchett told reporters in a briefing on Tuesday.

"We must endeavor to take pandemic threats off the table if we can," he said.

Hatchett said that delivering COVID-19 vaccines within 11 months was unprecedented, but not good enough. Had they been developed within 100 days, CEPI's pandemic goal, a COVID-19 vaccine could have been available as early as April 2020.

Dr. Jeremy Farrar, director of Wellcome, said an important lesson from the pandemic has been the need to have systems in place that allow for a rapid response when a crisis arrives.

"None of us believe Omicron will be the last variant or that COVID-19 will be the last pandemic," he said.

Bill Gates, co-chair of the Gates Foundation, said research and development investment should be commensurate with the future risk of pandemics.

The latest Gates pledge brings the charity's investment in CEPI to $270 million over the last five years, and its total pandemic investment to $2 billion.

"We want the world not to forget about how bad this pandemic was," he said.

CEPI made early investments in 14 COVID-19 vaccine candidates, including those from Oxford-AstraZeneca and Novavax, which recently received a World Health Organization emergency listing.

The group is also working on next-generation COVID-19 vaccines effective across variants and future coronaviruses in the same family. (Reporting by Julie Steenhuysen; Editing by Bill Berkrot)

© Reuters 2022
Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC -0.29% 10562 Delayed Quote.22.15%
BELIEVE -1.15% 9.465 Real-time Quote.-43.34%
ENDEAVOR GROUP HOLDINGS, INC. 4.02% 21.75 Delayed Quote.-37.66%
NOVAVAX, INC. -3.78% 51.4 Delayed Quote.-64.07%
ON SEMICONDUCTOR CORPORATION -1.01% 55.89 Delayed Quote.-17.71%
All news about ASTRAZENECA PLC
03:58aAstraZeneca COVID-19 vaccine approved in the EU as third dose booster against COVID-19
02:12aTrial Scheduled For April 2024 In BMS Patent Case Against AstraZeneca Regarding Anti-PD..
05/23EU Drug Regulator Approves AstraZeneca's COVID-19 Vaccine as Third-Dose Booster
05/23U.S. Task Force to consider routine kidney disease screening as new drugs available
05/23Indian vaccine giant Serum plans African plant in global expansion
05/23What you need to know about the coronavirus right now
05/23AstraZeneca's COVID-19 Vaccine Gets EU Approval as Third Booster Dose
05/23AstraZeneca aims to transform cancer care with practice-changing data at ASCO 2022
05/23AstraZeneca says COVID shot approved in EU as booster
05/23AstraZeneca's Covid-19 Vaccine Gets EU Approval for Third Doses
More news
Analyst Recommendations on ASTRAZENECA PLC
More recommendations
Financials (USD)
Sales 2022 43 702 M - -
Net income 2022 5 290 M - -
Net Debt 2022 22 652 M - -
P/E ratio 2022 39,1x
Yield 2022 2,21%
Capitalization 207 B 207 B -
EV / Sales 2022 5,24x
EV / Sales 2023 4,80x
Nbr of Employees 83 100
Free-Float 96,4%
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | AZN | GB0009895292 | MarketScreener
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 25
Last Close Price 133,28 $
Average target price 143,00 $
Spread / Average Target 7,30%
EPS Revisions
Managers and Directors
Pascal Soriot Chief Executive Officer & Executive Director
Aradhana Sarin Chief Financial Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Menelas NICOLAS Pangalos EVP-Biopharmaceuticals Research & Development
Pam P. Cheng Executive VP-Operations & Information Technology
Sector and Competitors
1st jan.Capi. (M$)
ASTRAZENECA PLC22.15%206 509
JOHNSON & JOHNSON4.89%472 179
PFIZER, INC.-10.45%296 704
ROCHE HOLDING AG-14.40%273 052
ABBVIE INC.9.33%261 585